NLS Pharmaceutics (NLSP) Regains Nasdaq Compliance

NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) today announced that it has received notice from the Nasdaq Stock Market LLC ("NASDAQ") informing the Company that it has regained full compliance with the bid price requirement in Listing Rule 5550(a)(2) and the equity requirement in Listing Rule 5550(b)(1).

"We are pleased to report that Nasdaq has recognized our full compliance with their listing requirements," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics. "Their confirmation follows our successful efforts to improve our balance sheet, including raising new capital and implementing a reverse share split."

You May Also Be Interested In

• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• Roots Corporation to go private in C$4.10-per-share deal with Marquee Brands
• Holcim to acquire Fermacell from James Hardie for EUR 840M